Vital KSK Holdings, Inc. Revises Consolidated Earnings Guidance for the Year Ended March 31, 2024
February 07, 2024 at 05:00 am
Share
Vital KSK Holdings, Inc. revised consolidated earnings guidance for the year ended March 31, 2024. For the year, the company revises net sales of JPY 584,000 million, operating profit of JPY 5,200 million, Profit attributable to owners of parent of JPY 5,500 million or JPY 108.27 basic earnings per share.
VITAL KSK HOLDINGS, INC. is a Japan-based holding company, principally engaged in the wholesale of drugs. The Pharmaceutical Wholesale segment is engaged in the wholesale of pharmaceuticals, diagnostics, medical equipment, materials to hospitals, medical practitioners, pharmacies and other medical institutions. The others business is engaged in dispensing pharmacy business, retail of pharmaceutical products, wholesale of agricultural chemicals and veterinary drugs, transportation business, nursing care business, consulting services for medical institutions, property insurance agency business, real estate brokerage business, as well as parking business.